Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5939
    +0.0004 (+0.07%)
     

  • NZD/EUR

    0.5546
    +0.0005 (+0.09%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.93
    -0.43 (-0.52%)
     

  • GOLD

    2,334.60
    -7.50 (-0.32%)
     

  • NASDAQ

    17,527.97
    +56.50 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,484.28
    -19.41 (-0.05%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • NZD/JPY

    92.1120
    +0.3460 (+0.38%)
     

Johnson & Johnson’s Revenue Estimates for 1Q18

Mike Benson
Updated
Johnson & Johnson’s Revenue Estimates for 1Q18

As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

Continue reading